FDA Fast Track - Metastatic Breast Cancer Trial Talk

Inside Clinical Trials

FDA Fast Track is a program to accelerate the development, review, and approval of new drugs to fill an unmet medical need, such as treatment for metastatic breast cancer. FDA Fast Track can help patients access new drugs earlier and help pharmaceutical companies save significant amounts of time in performing phase I, II, III, or even phase IV clinical trials for new drugs. 

FDA Fast Track approval is based on limited clinical trial data. Therefore, some drugs initially approved through the FDA Fast Track program can later be suspended or withdrawn from the market due to their lack of long-term benefits or because of safety concerns.

Read more about FDA Fast Track and its impact on patients. 



for past articles or specific information.